TILT Biotherapeutics Ltd.
Haartmaninkatu 3, 4th Floor
About TILT Biotherapeutics Ltd.TILT Biotherapeutics Ltd is a preclinical stage company working in the field of cancer immunotherapy. TILT aims to translate its unique approach into clinical trials. The company’s patented technology involves utilization of oncolytic viruses for enhancement of tumor T-cell therapy. Initial embodiments of the technology will be used to enhance tumor infiltrating lymphocyte (TIL), chimeric antigen receptor (CAR) and checkpoint inhibiting antibody therapy. The TILT approach has the potential to achieve similar results in CAR therapy of solid tumors as currently achieved for CD19+ hematological tumors.
Founder and CEO: Akseli Hemminki
6 articles with TILT Biotherapeutics Ltd.
EUR 18m raised to date, with investors including Lifeline Ventures, Finnish private investors, the European Innovation Council and Business Finland
TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123
TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China.
Engagement highlights TILT’s renewed focus on corporate communication
TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab
Agreement to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.
TILT Biotherapeutics Ltd has won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument.